- Home
- ATOS vs SLGL Comparison
ATOS vs SLGL Comparison
Compare ATOS & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATOS | SLGL |
|---|---|---|
| Founded | 2009 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.2M | 247.1M |
| IPO Year | 2010 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ATOS | SLGL |
|---|---|---|
| Price | $4.99 | $86.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $31.67 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 89.0K | 11.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,758.00 | N/A |
| Revenue This Year | N/A | $122.71 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $0.40 |
| 52 Week High | $7.56 | $97.97 |
Technical Indicators
Market Signals| Indicator | ATOS | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 66.34 | 52.34 |
| Support Level | $0.68 | $32.56 |
| Resistance Level | $5.12 | $97.97 |
| Average True Range (ATR) | 0.35 | 11.37 |
| MACD | -0.06 | -1.20 |
| Stochastic Oscillator | 72.46 | 44.14 |
Price Performance
Historical ComparisonAbout ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.